Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND”, the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY”.
For further information visit: https://www.clearmindmedicine.com
- Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
- Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
- Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
Strong, seasoned management team, and with alliances in place to expedite time-to-market and to de-risk CMN drug development programs.
CMND expects to launch our innovative MEAI-based drug candidate CMND-100 in human clinical trials with the FDA.
Massive verticals are within reach – CMND is targeting new treatments for Alcohol Use Disorder, depression, eating disorders, cocaine addiction, and other binge behaviors.
Stellar scientific advisory board with the additions of Yale’s Chair of Psychiatry Department, Prof. John Krystal, and two world-renowned experts in substance use and mental health, Prof. Christian Schütz from the University of British Columbia, Canada and Prof. Mark Weiser from Sheba Medical Centre, Israel.
Novel, patent-pending treatment for cocaine addiction.
U.S. Patent and Trademark Office extends protection of Clearmind’s proprietary MEAI and expands its potential market. The market for such non-alcoholic beverages in the U.S. in August 2022 stood at $395 million per year, showing a year-on-year growth of +20.6%.
As of 12/22/2022:
|
Market Cap |
9.692M |
|
52 Week Range |
3.0000 – 6.1000 |
|
Volume |
8,312 |
|
Avg. Volume |
127,561 |
